Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

cabazitaxel 3Trastuzumab 3Cyclophosphamide 2Cetuximab 2Carboplatin 2Aspirin 2ribociclib 1pertuzumab 1eribulin 1Thiotepa 1Taxes 1Stem Cell Transplantation 1Propofol 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neoadjuvant Therapy 1Liquid Biopsy 1Letrozole 1Ipilimumab 1Histamine H2 Antagonists 1Histamine Antagonists 1Gemcitabine 1Fulvestrant 1Epirubicin 1Docetaxel 1Denosumab 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1CA-72-4 antigen 1CA-19-9 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplastic Cells, Circulating × Liquid Biopsy × Clear all
NCT06067503 2026-04-13

Biomarkers to Detect Endocrine Therapy Resistance

University of Wisconsin, Madison

Phase 2 Recruiting
8 enrolled
Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡